**ITEMS CONSIDERED OUT OF SESSION BETWEEN ORDINARY MEETINGS (NOVEMBER 2024 – MARCH 2025)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SPONSOR, TYPE OF SUBMISSION** | **DRUG TYPE AND USE** | **LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION** | **PBAC OUTCOME** | |
| RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE  Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg  Ryeqo®  GEDEON RICHTER AUSTRALIA PTY LTD  (Other matters) | Endometriosis | To request reconsideration of the utilisation and financial estimates of the General Schedule Authority Required (STREAMLINED) listing for the treatment of moderate to severe pain associated with endometriosis. | Advice provided | The PBAC noted further revised financial estimates for Ryeqo provided by the sponsor following its positive recommendation in March 2024 and subsequent review of a proposal in November 2024. The PBAC acknowledged there remained some uncertainties with the utilisation estimates, but considered on balance the revised financial estimates were reasonable and a suitable basis for the Risk Sharing Arrangement (RSA) subsidisation caps. |